Accessibility Menu
Faeth Therapeutics logo

Faeth Therapeutics(NASDAQ) FTH

Market Cap$738.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-92%
5 Year-82%
1 Year+273%
1 Month-21%
$30.00
+5.01%
+1.43Today
After hours$30.00+$0.00 (+0.00%)
Faeth Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 28.572026-08-10
Faeth Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+4.5%USD 27.342026-08-03
1 month-20.99%USD 36.162026-07-10
3 month+36.05%USD 21.002026-05-12
Year to date+167.76%USD 10.672025-12-31
1 year+273.46%USD 7.652025-08-08
3 year+23.15%USD 23.202023-08-11
5 year-82.03%USD 159.002021-08-11
Since inception-92.44%USD 378.002021-02-04

Faeth Therapeutics Financials at a Glance

Market Cap

$738.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

-$4.85M

Net Income (TTM)

-$195.53M

EPS (TTM)

-$142.73

P/E Ratio

-0.20

Dividend

$0.00

Beta (Volatility)

1.00 (Low)

Price

$30.00

Volume

217,444.562

Open

$28.33

Previous Close

$30.00

Daily Range

$27.24 - $31.25

52-Week Range

$7.21 - $37.90

Estimated Earnings Date

Nov 13, 2026

FTH News

Foolcom-Featured.png

Sensei (SNSE) Q2 Loss Narrows 31%

Motley Fool Markets TeamAug 6, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Faeth Therapeutics

Sensei Biotherapeutics develops new cancer treatments using the body’s immune system. Its main products aim to help patients with advanced cancers. The company’s therapies are designed for people who need more effective cancer options.

Lab Bench to Bedside: What Sensei Sells

  • Solnerstotug (SNS-101): Monoclonal antibody in clinical trials for advanced solid tumors; 0% of revenue as of Q2 2025.
  • Preclinical Antibodies: Early-stage drugs targeting immune system proteins; 0% of revenue as of Q2 2025.
  • ImmunoPhage Platform: Vaccine technology for cancer, currently paused; 0% of revenue as of Q2 2025.
  • Research Collaborations: Joint projects with universities, such as a vaccine for rare skin cancer; 0% of revenue as of Q2 2025.

Growth Spurts and Strategic Pivots

  • Restructured in November 2024, closing its main research site and reducing staff by 46%.
  • Paused most early-stage programs in 2024 to focus on solnerstotug clinical trials.
  • Formed a partnership with Regeneron in January 2023 to test drug combinations.
  • Collaborated with University of Washington on a rare cancer vaccine, now paused.

Why Sensei’s Approach Stands Out

Sensei uses targeted antibodies that only activate in tumors, aiming to reduce side effects. Its focus on biomarker-driven trials helps match treatments to specific patient groups. The company’s streamlined structure concentrates resources on its lead drug candidate.

Five Things You Need to Know

  • No product revenue reported for Q2 2025, Q2 2024, or Q2 2023.
  • Net loss was $11.8 million in H1 2025, compared to $15.1 million in H1 2024.
  • Operating expenses were $12.5 million in H1 2025, compared to $16.5 million in H1 2024.
  • Cash and marketable securities totaled $28.6 million as of June 30, 2025.
  • Company expects current funds to last into Q2 2026, with no external funding secured.

Bottom Line

Sensei has narrowed its focus to one main cancer drug and reduced costs. Its future depends on successful trials and securing new funding.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

29

CEO

Christopher W. Gerry

Website

senseibio.com

Headquarters

Rockville, MD 20850, US

FTH Financials

Key Financial Metrics (TTM)

Gross Margin

2740.82%

Operating Margin

4098.54%

Net Income Margin

4030.69%

Return on Equity

-192.76%

Return on Capital

-110.88%

Return on Assets

-103.29%

Earnings Yield

-5.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$738.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

25.84M

Volume

217.44K

Avg. Volume

163.54K

Financials (TTM)

Gross Profit

-$132.96M

Operating Income

-$198.82M

EBITDA

-$195.40M

Operating Cash Flow

-$33.86M

Capital Expenditure

-$6.00K

Free Cash Flow

-$33.86M

Cash & ST Invst.

$186.44M

Total Debt

$592.00K

Faeth Therapeutics Performance Analysis

Faeth Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Faeth Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31100.0%
Q12026-03-31N/A
Q22026-06-30N/A
Faeth Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -31.6519.2%
20232023-12-31USD -24.40-22.9%
20242024-12-31USD -24.01-1.6%
20252025-12-31USD -16.72-30.4%
Faeth Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-307.4%
Q42025-12-31-3.3%
Q12026-03-31-3414.7%
Q22026-06-3097.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$738.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$25.46M

N/A

Employees

29

N/A

Net Income

-$16.01M

-224.3%

EBITDA

-$15.98M

-226.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$186.44M

+551.3%

Total Debt

$592.00K

-76.9%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$1.18M

-39.7%

Return on Assets

-1.03%

N/A

Return on Invested Capital

-1.11%

N/A

Free Cash Flow

-$15.67M

-164.5%

Operating Cash Flow

-$15.67M

-165.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CINGCingulate Inc.
$5.20-0.95%
DWTXDogwood Therapeutics, Inc.
$1.84+2.22%
CLRBCellectar Biosciences, Inc.
$2.64+1.54%
MRKRMarker Therapeutics, Inc.
$1.12-2.61%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$97.71+0.00%
SPCXSpace Exploration Technologies
$133.29-0.04%
NVDANvidia
$217.50-0.00%
SMCISuper Micro Computer
$31.60+0.00%

Questions About FTH

What is the current price of Faeth Therapeutics?

Faeth Therapeutics is trading at $30.00 per share.

What is the 52-week range for Faeth Therapeutics?

Over the past 52 weeks, Faeth Therapeutics has traded between $7.21 and $37.90.

How much debt does Faeth Therapeutics have?

As of the most recent reporting period, Faeth Therapeutics reported total debt of $1.04M.

How much cash does Faeth Therapeutics have on hand?

Faeth Therapeutics reported $152.33M in cash and cash equivalents in its most recent financial results.

What is Faeth Therapeutics’s dividend yield?

Faeth Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services